148 related articles for article (PubMed ID: 6940656)
21. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
22. Clinical studies of aclacinomycin A (ACM).
Majima H; Ohta K
Biomed Pharmacother; 1987; 41(5):233-7. PubMed ID: 3311189
[TBL] [Abstract][Full Text] [Related]
23. Phase I and pharmacological studies of pentamethylmelamine administered by 24-hour intravenous infusion.
Casper ES; Gralla RJ; Lynch GR; Jones BR; Woodcock TM; Gordon C; Kelsen DP; Young CW
Cancer Res; 1981 Apr; 41(4):1402-6. PubMed ID: 6783296
[TBL] [Abstract][Full Text] [Related]
24. [Pilot studies with aclacinomycin in patients with breast cancer or gastrointestinal tumors].
Rainer H; Gössinger H; Lenzhofer R; Moser K; Schneeweiss B
Wien Med Wochenschr; 1983; 133(7):183-7. PubMed ID: 6868630
[TBL] [Abstract][Full Text] [Related]
25. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
[TBL] [Abstract][Full Text] [Related]
26. Aclacinomycin A. Phase II evaluation in bronchogenic squamous-cell carcinoma.
Pazdur R; Samson MK; Baker LH
Am J Clin Oncol; 1987 Jun; 10(3):234-6. PubMed ID: 3473923
[TBL] [Abstract][Full Text] [Related]
27. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP
Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397
[TBL] [Abstract][Full Text] [Related]
28. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
30. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
Berman E; Wittes RE; Leyland-Jones B; Casper ES; Gralla RJ; Howard J; Williams L; Baratz R; Young CW
Cancer Res; 1983 Dec; 43(12 Pt 1):6096-101. PubMed ID: 6580068
[TBL] [Abstract][Full Text] [Related]
31. [A phase I trial of 4'-epiadriamycin].
Ogawa M; Ikeda K; Inagaki J; Horikoshi N; Inoue K; Nakada K; Usui N; Okada Y; Adachi K; Tada A
Gan To Kagaku Ryoho; 1984 Apr; 11(4):926-9. PubMed ID: 6586111
[TBL] [Abstract][Full Text] [Related]
32. Aclacinomycin A. Phase II evaluation in advanced soft tissue sarcoma.
Pazdur R; Samson MK; Baker LH
Am J Clin Oncol; 1987 Jun; 10(3):237-9. PubMed ID: 3473924
[TBL] [Abstract][Full Text] [Related]
33. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Hidalgo M; Buckner JC; Erlichman C; Pollack MS; Boni JP; Dukart G; Marshall B; Speicher L; Moore L; Rowinsky EK
Clin Cancer Res; 2006 Oct; 12(19):5755-63. PubMed ID: 17020981
[TBL] [Abstract][Full Text] [Related]
34. [Phase I and pharmacokinetic study of SM-5887 by 5-day schedule].
Inoue K; Matsumura A; Horikoshi N; Aiba K; Mukaiyama T; Matsumura T; Ogihara A; Sumida T; Ogawa M
Gan To Kagaku Ryoho; 1992 Apr; 19(4):477-82. PubMed ID: 1558397
[TBL] [Abstract][Full Text] [Related]
35. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
[TBL] [Abstract][Full Text] [Related]
36. [Phase I study of SM-5887, a new anthracycline derivative].
Inoue K; Ogawa M; Horikoshi N; Mukaiyama T; Itoh Y; Imajoh K; Ozeki H; Nagamine D; Shinagawa K
Gan To Kagaku Ryoho; 1988 May; 15(5):1771-6. PubMed ID: 3369871
[TBL] [Abstract][Full Text] [Related]
37. Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial.
Gockerman JP; Raney M; Logan T
Cancer Treat Rep; 1985 Sep; 69(9):1029-30. PubMed ID: 3861247
[No Abstract] [Full Text] [Related]
38. Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule.
Schilcher RB; Young JD; Leichman LP; Haas CD; Baker LH
Cancer Res; 1983 Aug; 43(8):3907-11. PubMed ID: 6683127
[TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
40. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
